Norwegian is available via eTranslation, the European Commission's machine translation service.
Translate to Norwegian | Important information about machine translation
The burden of cancer is increasing in Europe, which accounts for a tenth of the world’s population but a quarter of cancer cases recorded worldwide.
In the EU, without decisive action, lives lost to cancer are set to increase by more than 24% by 2035, according to the European Commission's 'Beating cancer plan'.
To help combat this threat, EMA is exploring how to improve medicine evaluation by using cancer as a pathfinder.
Launched in 2023, Cancer Medicines Pathfinder could have a meaningful impact for patient care and access to innovative therapies.
For more information on cancer medicines and the burden of cancer in Europe, see:
EMA's Cancer Medicines Pathfinder groups its initiatives under three pillars:
The Cancer Medicines Pathfinder project helps accelerates development and assessment of cancer medicines by identifying high-priority medicines that can address unmet medical needs.
The project builds on the European medicines regulatory network's experience in responding and adapting to the COVID-19 pandemic.
Key to this response was to accelerate development and assessment on COVID-19 medicines.
For more information, see:
EMA's collaboration with the United States (US) Food and Drug Administration (FDA) is an example of both multi-stakeholder dialogue and international collaboration.
EMA exchanges information with FDA and promotes its projects in areas such as oncology education and patient engagement.
For more information, see:
EMA launched a monthly newsletter featuring related news, regulatory actions and activities in oncology.
For more information, see:
An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.
The tracking of updates begins in October 2026.
16 October 2026
'Accelerate development and assessment of cancer medicines critical to patient care' subsection under the 'Pathfinder initiatives' section updated to include information on the project's role in identifying medicines that can address unment medical needs.